Faming Zhang Ph.D

        Faming Zhang is the founder and CEO of Waterstone Pharmaceuticals, Inc. He also served as President

        of Crown Bioscience Inc., a leading preclinical biology CRO company.  Prior to founding Waterstone and

        Crownbio, Dr. Zhang has spent 12 years at Eli Lilly & Co. withthe responsibility as the global head of

        Drug Discovery and Development Information Sciences. Dr. Zhang led Lilly’s protein kinase structure-

        based drug design platform. He is the co-inventor of several patents in the area of kinase inhibitors and

        novel anti-obesity protein therapeutics. He also played a major role in the progression of cell cycle kinase

inhibitors to the clinic. Dr. Zhang received his Ph.D in Biochemistry and Molecular Biology from Inst. of Biophysics, Chinese

Academy of Sciences and an MBA from Kelly Business School, Indiana University. He had 4 year of postdoctoral training from

University of Texas Southwestern Medical Center in Dallas. He was also an Assoc. Professor of Chemistry and Biochemistry at

Indiana University Bloomington.

 

          Howard Lee Ph.D

        Dr. Howard S. Lee, Partner, is responsible for Life Science investment of The CID Group. Dr. Lee has

                 over sixteen years experience in investment banking, global healthcare venture capital and project

                 management fields. Prior to joining CID Group, Dr. Lee was a Managing Director of Easy Life Science

                 Management Inc. He was the Chief Investment Officer of UniMed Venture Management Inc., a

                 Taiwan biomedical venture capital firm from July 1st, 2009 to Oct. 31st 2010. He also used to be a

                 Managing Director at Silver Biotech Management, Inc. (SBM) for three years. SBM served as general

                 partner for Coller Capital,and managed two biotech funds, Coller Partners 403, L.P. and Formosa

          Healthcare Investments L.P. with fund size of US$100M. Dr. Lee used to serve as President & CEO of CDIB Biotech USA

          Investment Co. Ltd., from October 2000 to June 2006, he also served as Vice President of China Development Industrial

          Bank, a prominent investment bank in Taiwan, from October 1995 to June 2006. During the eleven years,  Dr. Lee led

          more than US$200M of global equity investment in healthcare industry. Before then, Dr. Lee accumulated broad industrial

          experience from conducting environmental engineering projects in diversified industries since 1992.



            Ivy Chang

                Ivy is a seasoned finance executive with deep experience in the US and Chinese markets. She received

                her BS degree on Public Finance from National Chung Hsing University, Taiwan and MBA Concentrating 

                in Accounting from   Ohio State University, United States. She advenced her career from cost 

                accountant,Controller to EVP of Finance in a variety of companies including Ricoh Electronics (Irvine, 

                CA), SINA.com (Sunnyvale, CA), iMedica Corp (Mountain View, CA). She was the CFO of Chinese 

                Future Corp. and Shanghai Capgen Investment Company while she let the US$100M fund raising 

               by selling 25% of the company shares to a British Fund in 2005 and raised US$225M in capital market 

          by issuing a corporate bond and guided a corporate loan of RMB 5.2B from ICBC. She is also a board director of Shanghai 

          Taiwanese Children School.



          Jonathan Wang Ph.D

      Dr. Jonathan Wang is a Senior Managing Director, Asia at OrbiMed.  With over 20 years of healthcare

               and life sciences experience, spanning investment, finance and research, he has co-founded OrbiMed

               Asia.  Previously, he was a Partner at Legend Capital and General Manager, Greater China at Burrill &

               Company. He also worked for WI Harper Group, where he was a Managing Director overseeing the

               firm’s life sciences activities worldwide, and Walden International. He was a Board Director at ForteBio,

               Inc. (acquired by Pall Corporation) and is Chairman at Bonovo Orthopedics, Inc. He is a Board Director

               at EA, Inc. (formerly Chairman), Response Biomedical Corporation (TSE: RBM) and Waterstone

          Pharmaceuticals, Inc.  He is a co-founder and former Chairman of The BayHelix Group, a premier organization of Chinese life

          sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he obtained scientific

          training under the supervision of Dr. Eric Kandel, a Nobel Laureate. He was rewarded the Howard Hughes Medical Institute

          (HHMI) Research Fellowship at Columbia. He also earned an MBA from Stanford University.

About
Company Profile
Management Team
Board of Directors
Vision & Mission
Corporate History
Capability
Capability
Advantage
Products
Drug Products
APIs
Intermediates
Fine chemicals
Investors
BAR Capital
Acorn Campus Ventures
CID Group
Orbimed
News
Company News
Media Reports
Publications
Contacts
Location & massage
Career